Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the United States, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market...
Website: bio-rad.com


  • Pretty weak financial results growth rate 4.2% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (3.6%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -2.7% (LTM)
  • Share price is 44.4% higher than minimum and 37.8% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (23.4x vs 21.2x)
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $0.2 mln (-0.002% of cap.)

Key Financials (Download financials)

Ticker: BIO
Share price, USD:  (-0.2%)312.76
year average price 278.91  


year start price 360.54 2025-01-22

max close price 360.88 2025-01-31

min close price 216.56 2025-06-02

current price 312.76 2026-01-21
Common stocks: 29 733 400

Dividend Yield:  0.0%
FCF Yield LTM: -2.7%
EV / LTM EBITDA: 23.4x
EV / EBITDA annualized: 20.6x
Last revenue growth (y/y):  +0.5%
Last growth of EBITDA (y/y):  +7.8%
Historical revenue growth:  -3.0%
Historical growth of EBITDA:  +10.2%
EV / Sales: 3.6x
Margin (EBITDA LTM / Revenue): 15.2%

Target EV / EBITDA (hist percentile): 21.2x
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 9 299
Net Debt ($m): -216
EV (Enterprise Value): 9 083
EBITDA LTM (млн $): 389
EV / LTM EBITDA: 23.4x
Price to Book: 1.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-11-14globenewswire.com

Digital Identity and Biometric Access Management Provider BIO-key Reports Q3 Results; Highlights Enhanced Post Quarter Balance Sheet to Support 2026 Growth Goals; Holds Investor Call 10am ET Today

2025-11-12globenewswire.com

BIO-key Partners with VaporVM to Expand Reach of its Advanced Identity and Access Management and Biometric Cybersecurity Solutions in Middle East and Africa

2025-11-10globenewswire.com

BIO-key Showcases Biometric Identity Innovations at Africa Tech Festival 2025, November 10-13

2025-11-07globenewswire.com

BIO-key Secures Significant Identity and Biometric Security Deployment with a Major Middle East Defense Sector Organisation

2025-11-05prnewswire.com

BIO-TECHNE DECLARES DIVIDEND

2025-10-27globenewswire.com

BIO-key International and IT2Trust Partner to Strengthen IAM and Biometric Security Across the Nordic Region of Denmark, Sweden, Norway and Finland

2025-10-16businesswire.com

Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025

2025-10-15globenewswire.com

BIO-key Showcases Next-Generation Identity & Biometric Authentication Solutions at Premier Tech and Cybersecurity Events: GITEX 2025 in Dubai and 19ENISE in Spain

2025-09-19businesswire.com

89BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB

2025-09-04seekingalpha.com

Bio-Rad Laboratories, Inc. (BIO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208
fillingDate 2025-10-29 2025-07-31 2024-10-31 2024-08-02 2024-05-08 2024-02-16 2023-10-27 2023-08-04 2023-05-05 2023-02-17 2022-10-28
acceptedDate 2025-10-29 16:18:31 2025-07-31 16:17:43 2024-10-31 16:14:35 2024-08-02 16:15:19 2024-05-08 16:31:24 2024-02-16 16:31:26 2023-10-27 16:31:15 2023-08-04 16:31:06 2023-05-05 16:31:07 2023-02-17 17:07:55 2022-10-28 17:13:50
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 653M 652M 650M 638M 611M 681M 632M 681M 677M 730M 681M
costOfRevenue 310M 306M 294M 283M 284M 315M 296M 319M 314M 333M 307M
grossProfit 343M 345M 356M 356M 326M 366M 336M 362M 362M 397M 374M
grossProfitRatio 0.526 0.53 0.548 0.557 0.534 0.537 0.531 0.532 0.535 0.544 0.549
researchAndDevelopmentExpenses 71M 61M 91M 59M 64M 62M 44M 65M 75M 66M 70M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 207M 208M 200M 196M 210M 206M 201M 208M 226M 212M 211M
otherExpenses 0 0 0 2M 700 000 -65 000 20M 16M 50M 2M 0
operatingExpenses 278M 268M 291M 255M 274M 268M 245M 273M 301M 278M 281M
costAndExpenses 588M 575M 585M 538M 559M 583M 541M 591M 615M 612M 588M
interestIncome 0 15M 16M 17M 34M 17M 17M 17M 0 12M 8M
interestExpense 12M 13M 12M 12M 12M 12M 12M 12M 12M 12M 12M
depreciationAndAmortization 34M 51M 49M 47M 48M 43 812 37M 36M 36M 42M 36M
ebitda -385M 477M 923M -2 727M 100M 151M 149M 142M 148M 161M 129M
ebitdaratio -0.589 0.732 1.42 0.23 0.163 0.221 0.235 0.208 0.219 0.22 0.189
operatingIncome 65M 77M 64M 100M 52M 98M 91M 90M 112M 119M 93M
operatingIncomeRatio 0.1 0.118 0.099 0.157 0.085 0.144 0.144 0.132 0.166 0.162 0.136
totalOtherIncomeExpensesNet -496M 337M 797M -2 888M 439M 331M 59M -1 578M -28M 973M -302M
incomeBeforeTax -431M 414M 862M -2 786M 491M 428M 137M -1 500M 85M 1 091M -209M
incomeBeforeTaxRatio -0.66 0.635 1.326 -4.364 0.804 0.629 0.217 -2.203 0.125 1.494 -0.307
incomeTaxExpense 89M 96M 208M -621M 107M 79M 31M -338M 16M 264M -45M
netIncome -342M 318M 653M -2 165M 384M 350M 106M -1 162M 69M 828M -164M
netIncomeRatio -0.524 0.488 1.005 -3.392 0.629 0.513 0.168 -1.706 0.102 1.133 -0.241
eps -12.7 11.67 23.37 -76.26 13.46 12.15 3.65 -39.59 2.33 27.89 -5.52
epsdiluted -12.7 11.67 23.34 -76.26 13.45 12.14 3.64 -39.59 2.32 27.78 -5.52
weightedAverageShsOut 27M 27M 28M 28M 29M 29M 29M 29M 30M 30M 30M
weightedAverageShsOutDil 27M 27M 28M 28M 29M 29M 29M 29M 30M 30M 30M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208
fillingDate 2025-10-29 2025-07-31 2024-10-31 2024-08-02 2024-05-08 2024-02-16 2023-10-27 2023-08-04 2023-05-05 2023-02-17 2022-10-28
acceptedDate 2025-10-29 16:18:31 2025-07-31 16:17:43 2024-10-31 16:14:35 2024-08-02 16:15:19 2024-05-08 16:31:24 2024-02-16 16:31:26 2023-10-27 16:31:15 2023-08-04 16:31:06 2023-05-05 16:31:07 2023-02-17 17:07:55 2022-10-28 17:13:50
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 398M 369M 412M 407M 433M 404M 458M 390M 464M 434M 518M
shortTermInvestments 1 023M 1 005M 1 212M 1 215M 1 218M 1 209M 1 307M 1 338M 1 393M 1 362M 1 338M
cashAndShortTermInvestments 1 421M 1 374M 1 622M 1 622M 1 651M 1 613M 1 765M 1 728M 1 857M 1 796M 1 856M
netReceivables 474M 470M 462M 455M 460M 501M 457M 492M 498M 495M 432M
inventory 783M 799M 804M 804M 783M 781M 776M 777M 753M 719M 686M
otherCurrentAssets 164M 169M 167M 175M 167M 154M 149M 142M 169M 148M 166M
totalCurrentAssets 2 842M 2 811M 3 056M 3 056M 3 061M 3 048M 3 147M 3 139M 3 277M 3 158M 3 140M
propertyPlantEquipmentNet 0 740M 719M 715M 711M 724M 711M 688M 681M 680M 633M
goodwill 579M 582M 415M 412M 413M 414M 407M 412M 408M 406M 400M
intangibleAssets 388M 397M 307M 307M 314M 321M 314M 329M 328M 332M 325M
goodwillAndIntangibleAssets 967M 979M 722M 719M 726M 734M 721M 740M 736M 739M 725M
longTermInvestments 5 058M 5 577M 6 003M 5 100M 8 019M 7 698M 7 218M 7 311M 8 879M 8 831M 7 459M
taxAssets 0 0 0 878M 1 541M 1 475 495M 1 370M 1 402M 1 769 781M 0 0
otherNonCurrentAssets 829M 108M 104M -781M -1 449M -1 475 401M -1 271M -1 302M -1 769 685M 95M 102M
totalNonCurrentAssets 6 854M 7 403M 7 548M 6 632M 9 549M 9 251M 8 749M 8 839M 10 390M 10 344M 8 918M
otherAssets 0 0 25 000 0 0 0 0 0 0 0 0
totalAssets 9 696M 10 214M 10 603M 9 688M 12 610M 12 299M 11 896M 11 978M 13 667M 13 502M 12 058M
accountPayables 129M 139M 122M 127M 103M 143M 267M 304M 335M 330M 335M
shortTermDebt 38M 41M 43M 42M 41M 41M 476 000 476 000 519 000 465 000 448 000
taxPayables 45M 36M 44M 36M 34M 35 759M 104M 74M 51M 32M 29M
deferredRevenue 0 0 0 -127M 34M 35 759M -112M 74M 0 52M 1 484 606M
otherCurrentLiabilities 311M 333M 289M 282M 289M -35 420M 403M 203M 254M 186M -1 484 371M
totalCurrentLiabilities 522M 549M 498M 487M 466M 523M 558M 582M 590M 569M 571M
longTermDebt 1 357M 1 366M 1 344M 1 351M 1 190M 1 189M 1 199M 1 198M 1 198M 1 198M 1 197M
deferredRevenueNonCurrent 0 0 -38 000 160M 169M 175M -1 370M -1 402M 0 1 770 481M 0
deferredTaxLiabilitiesNonCurrent 873M 961M 1 076M 878M 1 541M 1 475M 1 370M 1 402M 1 770M 1 770M 1 485M
otherNonCurrentLiabilities 208M 210M 198M 194M 192M 195M 1 723M 1 751M 346M -1 770 131M -1 481 907M
totalNonCurrentLiabilities 2 437M 2 537M 2 618M 2 423M 3 093M 3 035M 2 922M 2 949M 3 314M 3 318M 3 034M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 165M 204M 187M 202M 169M 175M 167M 147M 183M 190M 192M
totalLiabilities 2 960M 3 085M 3 116M 2 910M 3 559M 3 558M 3 480M 3 531M 3 904M 3 886M 3 605M
preferredStock 0 0 0 0 0 0 0 0 0 0 0
commonStock 0 0 3000 3000 3000 3000 3000 3000 3000 3000 3000
retainedEarnings 7 456M 7 798M 8 132M 7 479M 9 645M 9 261M 8 911M 8 805M 9 967M 9 898M 9 047M
accumulatedOtherComprehensiveIncomeLoss -167M -154M -315M -451M -426M -336M -498M -373M -408M -467M -845M
othertotalStockholdersEquity -553M -515M -329M -249M -167M -183M 3M 15M 205M 184M 252M
totalStockholdersEquity 6 737M 7 129M 7 488M 6 779M 9 051M 8 741M 8 416M 8 447M 9 764M 9 615M 8 454M
totalEquity 6 737M 7 129M 7 488M 6 779M 9 051M 8 741M 8 416M 8 447M 9 764M 9 615M 8 454M
totalLiabilitiesAndStockholdersEquity 9 696M 10 214M 10 603M 9 688M 12 610M 12 299M 11 896M 11 978M 13 667M 13 502M 12 058M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 9 696M 10 214M 10 603M 9 688M 12 610M 12 299M 11 896M 11 978M 13 667M 13 502M 12 058M
totalInvestments 6 081M 6 581M 7 215M 6 315M 9 237M 8 907M 8 525M 8 649M 10 271M 8 843M 8 797M
totalDebt 1 395M 1 407M 1 388M 1 393M 1 400M 1 406M 1 199M 1 199M 1 199M 1 198M 1 198M
netDebt 998M 1 037M 978M 985M 966M 1 002M 741M 809M 734M 764M 680M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208
fillingDate 2025-10-29 2025-07-31 2024-10-31 2024-08-02 2024-05-08 2024-02-16 2023-10-27 2023-08-04 2023-05-05 2023-02-17 2022-10-28
acceptedDate 2025-10-29 16:18:31 2025-07-31 16:17:43 2024-10-31 16:14:35 2024-08-02 16:15:19 2024-05-08 16:31:24 2024-02-16 16:31:26 2023-10-27 16:31:15 2023-08-04 16:31:06 2023-05-05 16:31:07 2023-02-17 17:07:55 2022-10-28 17:13:50
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -342M -120M 653M -2 165M 384M 350M 106M -1 162M 69M 833M -164M
depreciationAndAmortization 54M -38M 49M 47M 48M 53M 37M 36M 36M 40M 33M
deferredIncomeTax -88M 0 167M -659M 84M 75M -16M -13M -13 900 0 0
stockBasedCompensation 0 -15M -30M 15M 15M 16M 16M 13M 17M 18M 16M
changeInWorkingCapital -14M -44M 221M -24M -28M -94M 360M -16M -39M -63M -100M
accountsReceivables 4M -37M -33M -4M 37M -20M 26M 7M -1M -43M 1M
inventory 14M 18M 31M -22M -9M 15M -6M -25M -30M -8M -48M
accountsPayables -33M -30M 27M 18M -44M 21M -38M -43M 8M -25M -27M
otherWorkingCapital 1M 6M 196M -15M -13M -110M 378M 45M -16M 12M -27M
otherNonCashItems 511M 334M -896M 3 002M -307M -319M -406M 1 241M 16M -738M 224M
netCashProvidedByOperatingActivities 121M 117M 164M 98M 69M 81M 98M 98M 98M 90M 8M
investmentsInPropertyPlantAndEquipment -32M -46M -40M -42M -40M -42M -44M -35M -36M -47M -24M
acquisitionsNet 0 -217M 0 66 000 26 000 3M 44M 35M 36M 46M -101M
purchasesOfInvestments -224M -153M -399M -248M -406M -152M -196M -138M -204M -253M -329M
salesMaturitiesOfInvestments 214M 300M 407M 259M 404M -239M 231M 201M 169M 231M 369M
otherInvestingActivites -2M 0 -23M 11M 26 000 502M -44M -35M -36M -46M 6000
netCashUsedForInvestingActivites -43M -115M -56M -31M -43M 72M -10M 28M -70M -69M -85M
debtRepayment -300 000 -200 000 -123 000 -118 000 -118 000 -118 000 -118 000 -116 000 -115 000 -143 000 -113 000
commonStockIssued 3M 4M 0 0 6M 4M 5M 0 0 17 560M 0
commonStockRepurchased -53M -140M -98M -101M -5M -200M -21M 0 0 -91M -129M
dividendsPaid 0 0 -16M 0 -16M -85 439M 0 0 -14 662M -47 432M -30M
otherFinancingActivites -2M -100 000 18M 5M -617 000 85 434M -5M -203M 14 666M 29 876M 151M
netCashUsedProvidedByFinancingActivities -53M -136M -96M -97M 638 000 -201M -27M -203M 4M -87M -9M
effectOfForexChangesOnCash 1M -16M -8M 4M 3M -7M 6M 3M -2M -18M 8M
netChangeInCash 27M -151M 5M -26M 29M -54M 68M -74M 30M -84M -79M
cashAtEndOfPeriod 398M 372M 412M 407M 433M 404M 458M 390M 465M 435M 518M
cashAtBeginningOfPeriod 372M 523M 407M 433M 404M 458M 390M 465M 435M 518M 597M
operatingCashFlow 121M 117M 164M 98M 69M 81M 98M 98M 98M 90M 8M
capitalExpenditure -32M -46M -64M -42M -40M -42M -44M -35M -36M -47M -24M
freeCashFlow 89M 71M 100M 55M 29M 39M 54M 63M 62M 43M -17M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Earning call transcript

2025 q3
2025-10-29 ET (fiscal 2025 q3)
2025 q2
2025-07-31 ET (fiscal 2025 q2)
2025 q1
2025-05-01 ET (fiscal 2025 q1)
2024 q4
2025-02-13 ET (fiscal 2024 q4)
2024 q3
2024-10-30 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-07 ET (fiscal 2024 q1)
2023 q4
2024-02-15 ET (fiscal 2023 q4)
2023 q3
2023-10-26 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-16 ET (fiscal 2022 q4)
2022 q3
2022-10-27 ET (fiscal 2022 q3)
2022 q2
2022-07-28 ET (fiscal 2022 q2)
2022 q1
2022-04-28 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2025-10-29 20:18 ET
Bio-Rad Laboratories published news for 2025 q3
SEC form 8
2025-10-29 20:16 ET
Bio-Rad Laboratories published news for 2025 q3
SEC form 8
2025-10-29 20:16 ET
Bio-Rad Laboratories reported for 2025 q3
SEC form 8
2025-10-29 20:16 ET
Bio-Rad Laboratories published news for 2025 q3
SEC form 10
2025-07-31 20:17 ET
Bio-Rad Laboratories published news for 2025 q2
SEC form 8
2025-07-31 20:15 ET
Bio-Rad Laboratories published news for 2025 q2
SEC form 8
2025-07-31 20:15 ET
Bio-Rad Laboratories reported for 2025 q2
SEC form 8
2025-07-31 20:15 ET
Bio-Rad Laboratories published news for 2025 q2
SEC form 10
2025-05-01 20:30 ET
Bio-Rad Laboratories published news for 2025 q1
SEC form 8
2025-05-01 20:20 ET
Bio-Rad Laboratories published news for 2025 q1
SEC form 8
2025-05-01 20:20 ET
Bio-Rad Laboratories reported for 2025 q1
SEC form 10
2025-05-01 00:00 ET
Bio-Rad Laboratories published news for 2025 q1
SEC form 10
2025-02-14 16:30 ET
Bio-Rad Laboratories published news for 2024 q4
SEC form 10
2025-02-14 00:00 ET
Bio-Rad Laboratories published news for 2024 q4
SEC form 8
2025-02-13 16:28 ET
Bio-Rad Laboratories published news for 2024 q4
SEC form 8
2025-02-13 16:28 ET
Bio-Rad Laboratories reported for 2024 q4
SEC form 8
2025-02-13 16:28 ET
Bio-Rad Laboratories published news for 2024 q4
SEC form 10
2024-10-31 16:14 ET
Bio-Rad Laboratories reported for 2024 q3
SEC form 8
2024-10-30 16:17 ET
Bio-Rad Laboratories published news for 2024 q3
SEC form 8
2024-10-30 16:17 ET
Bio-Rad Laboratories published news for 2024 q3
SEC form 10
2024-08-02 16:15 ET
Bio-Rad Laboratories published news for 2024 q2
SEC form 10
2024-08-02 00:00 ET
Bio-Rad Laboratories published news for 2024 q2
SEC form 8
2024-08-01 16:18 ET
Bio-Rad Laboratories reported for 2024 q2
SEC form 8
2024-08-01 16:18 ET
Bio-Rad Laboratories published news for 2024 q2
SEC form 10
2024-05-08 00:00 ET
Bio-Rad Laboratories published news for 2024 q1
SEC form 8
2024-05-07 16:18 ET
Bio-Rad Laboratories published news for 2024 q1
SEC form 8
2024-05-07 16:18 ET
Bio-Rad Laboratories reported for 2024 q1
SEC form 10
2024-02-16 00:00 ET
Bio-Rad Laboratories published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Bio-Rad Laboratories published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Bio-Rad Laboratories reported for 2023 q4
SEC form 10
2023-10-27 16:31 ET
Bio-Rad Laboratories published news for 2023 q3
SEC form 10
2023-10-27 00:00 ET
Bio-Rad Laboratories published news for 2023 q3
SEC form 8
2023-10-26 16:17 ET
Bio-Rad Laboratories reported for 2023 q3
SEC form 10
2023-08-04 16:31 ET
Bio-Rad Laboratories published news for 2023 q2
SEC form 10
2023-08-04 00:00 ET
Bio-Rad Laboratories published news for 2023 q2
SEC form 6
2023-08-03 16:19 ET
Bio-Rad Laboratories reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Bio-Rad Laboratories published news for 2023 q2
SEC form 6
2023-07-20 16:31 ET
Bio-Rad Laboratories published news for 2023 q2
SEC form 6
2023-06-05 08:45 ET
Bio-Rad Laboratories published news for 2023 q1
SEC form 10
2023-05-05 00:00 ET
Bio-Rad Laboratories published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Bio-Rad Laboratories reported for 2023 q1
SEC form 10
2023-02-17 00:00 ET
Bio-Rad Laboratories reported for 2022 q4
SEC form 8
2023-02-16 00:00 ET
Bio-Rad Laboratories reported for 2022 q4
SEC form 10
2022-10-28 00:00 ET
Bio-Rad Laboratories reported for 2022 q3
SEC form 8
2022-10-27 00:00 ET
Bio-Rad Laboratories reported for 2022 q3
SEC form 10
2022-07-29 00:00 ET
Bio-Rad Laboratories reported for 2022 q2
SEC form 8
2022-07-28 00:00 ET
Bio-Rad Laboratories reported for 2022 q2
SEC form 10
2022-04-29 00:00 ET
Bio-Rad Laboratories reported for 2022 q1
SEC form 8
2022-04-28 00:00 ET
Bio-Rad Laboratories reported for 2022 q1
SEC form 10
2022-02-11 00:00 ET
Bio-Rad Laboratories published news for 2021 q4
SEC form 8
2022-02-10 00:00 ET
Bio-Rad Laboratories published news for 2021 q4
SEC form 10
2021-10-29 00:00 ET
Bio-Rad Laboratories published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
Bio-Rad Laboratories published news for 2021 q3
SEC form 10
2021-07-30 00:00 ET
Bio-Rad Laboratories published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
Bio-Rad Laboratories published news for 2021 q2
SEC form 10
2021-04-30 00:00 ET
Bio-Rad Laboratories published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
Bio-Rad Laboratories published news for 2021 q1